Three novel pentavalent meningococcal vaccines

Invasive meningococcal disease (IMD) is rare in travellers but associated with high mortality and long-term sequelae. Six serogroups (MenABCWXY) account for more than 90% of IMD. Three pentavalent vaccines are on the horizon: two MenABCWY, both with a 0-6 month schedule, highly immunogenic and well tolerated, and one single-dose MenACWXY.